Improving pre-operative binary grading: relevance of p53 and PR expression in grade 2 endometrioid endometrial carcinoma.

Summary: Solving the "Middle Child" Problem in Uterine Cancer

When doctors diagnose endometrial (uterine) cancer, they typically assign a grade: Grade 1 (slow-growing), Grade 3 (aggressive), or Grade 2 (somewhere in the middle). Grade 2 cases have always been the most difficult to treat because it is unclear if they will behave safely or aggressively.

A new European study involving over 1,000 women has found a solution. By testing Grade 2 tumors for two specific molecular markers—a protein called p53 and the Progesterone Receptor (PR)—doctors can now predict the future. If the tumor has normal p53 and positive PR, it behaves just like the safe Grade 1 cancer (96% survival). If these markers are abnormal, it behaves like the dangerous Grade 3 cancer. This suggests doctors should stop using the vague "Grade 2" label and instead use these markers to immediately classify patients as low or high risk, ensuring women get exactly the treatment they need—no more, no less.